Thromboangiitis Obliterans (TAO), a common peripheral vascular disease with a long illness course and grave sufferings, can cause acromelic gangrene, ulcer and even amputation at the late stage. We have for many years...Thromboangiitis Obliterans (TAO), a common peripheral vascular disease with a long illness course and grave sufferings, can cause acromelic gangrene, ulcer and even amputation at the late stage. We have for many years used TCM syndrome differentiation to diagnose and treat the disease with good therapeutic results. The treatment of 64 TAO cases from 2001 to 2002 is reported as follows.展开更多
Objective:To study the correlation of peripheral blood nuclear factorκB (NF-κB) expression with cytokines and endothelial injury in patients with thromboangiitis obliterans (TAO).Methods:Patients who were diagnosed ...Objective:To study the correlation of peripheral blood nuclear factorκB (NF-κB) expression with cytokines and endothelial injury in patients with thromboangiitis obliterans (TAO).Methods:Patients who were diagnosed as lower limb thromboangiitis obliterans in Jining No. 1 People's Hospital between March 2014 and October 2017 were selected as the TAO group of the research, and healthy subjects who received physical examination in Jining No. 1 People's Hospital during the same period and had the general information matching that of TAO group were selected as the control group. The NF-κB expression intensity in peripheral blood as well as the contents of cytokines and endothelial injury indexes in serum was determined.Results: NF-κB expression intensity in peripheral blood of TAO group was significantly higher than that of control group;serum ICAM-1, VCAM-1, E-selectin, TGF-β1, IL-10, TXB2, vWF, D-D, HIF-1 and VEGF levels of TAO group were significantly higher than those of control group whereas 6-Keto-PGF1 level was significantly lower than that of control group, and serum ICAM-1, VCAM-1, E-selectin, TGF-β1, IL-10, TXB2, vWF, D-D, HIF-1 and VEGF levels of TAO group of patients with high NF-κB expression were significantly higher than those of patients with low NF-κB expression whereas 6-Keto-PGF1 level was significantly lower than that of patients with low NF-κB expression.Conclusion: The high expression of NF-κB in the peripheral blood of patients with TAO can promote the excessive secretion of inflammatory and immune cytokines and aggravate the endothelial cell injury.展开更多
Thromboangiitis obliterans (TAO) is an unusual tobacco-associated vasculopathy that is a non- atherosclerotic inflammatory disorder of unkn- own etiology that affects small and medium- sized vessels of the extremities...Thromboangiitis obliterans (TAO) is an unusual tobacco-associated vasculopathy that is a non- atherosclerotic inflammatory disorder of unkn- own etiology that affects small and medium- sized vessels of the extremities. The single guanosine nucleotide deletion/insertion polym- orphism (4G/5G) at -675 bp in promoter region of the PAI-1 gene is the major genetic determi- nant of PAI-1 expression. Plasma PAI-1 level is higher in people with the homozygous 4G genotype than in those with the 5G/5G genotype and renders higher transcription activity. The aim of this study was to determine the status and the role of PAI-1 gene 4G/5G promoter polymorphism in patients with Buerger's disease (Thromboangiitis obliterans—TAO). The current case-control study included 30 consecutive pat- ients with Buerger's disease (mean age 42.9 ± 14.3 years, 28 men and 2 women), and 30 healthy volunteers (mean age 40.9 ± 4.79 years, 27 men and 3 women) between January 2006 and September 2009. Patients and control cases were genotyped for the 4G/5G polymorphism using the multiplex PCR based stripassay reverse hybridisation technique. It was found that heterozygote PAI-1 gene polymorphisms (p < 0.05) was significantly more frequent in patients with TAO in the current results. There was a significant difference in genotype distribution between the two groups (P < 0.001). The 4G allele occurred more frequently in the patient group of heavy smokers (P = 0.05). The current study shows the higher prevalence of of 4G allele in TAO patients in Sivas population means gene may predispose to TAO.展开更多
Thromboangiitis obliterans(TAO)is a rare,chronic,progressive,and segmental inflammatory disease characterized by a high rate of amputation,significantly compromising the quality of life of patients.Si-Miao-Yong-An dec...Thromboangiitis obliterans(TAO)is a rare,chronic,progressive,and segmental inflammatory disease characterized by a high rate of amputation,significantly compromising the quality of life of patients.Si-Miao-Yong-An decoction(SMYA),a tradition-al prescription,exhibits anti-inflammatory,anti-thrombotic,and various other pharmacological properties.Clinically,it was fully proved to be effective for TAO therapy,but the specific therapeutic effect of SMYA on TAO has been unknown.Thus,deep unveiling the mechanism of SMYA in TAO for identifying clinical therapeutic targets is extremely important.In this study,we observed elev-ated levels of IL-17A in the peripheral blood mononuclear cells(PBMCs)of TAO patients,whereas the expression of miR-548j-5p was significantly decreased.A negative correlation between the levels of miR-548j-5p and IL-17A was also demonstrated.In vitro ex-periments showed that overexpression of miR-548j-5p led to a decrease in IL-17A levels,whereas downregulation of miR-548j-5p showed the opposite effect.Using a dual luciferase assay,we confirmed that miR-548j-5p directly targets IL-17A.Furthermore,serum containing SMYA effectively decreased IL-17A levels by increasing the expression of miR-548j-5p.More importantly,the results of in vivo tests indicated that SMYA mitigated the development of TAO by inhibiting IL-17A through the upregulation of miR-548j-5p in vascular tissues.In conclusion,SMYA significantly enhances the expression of miR-548j-5p,thereby reducing the levels of the target gene IL-17A and alleviating TAO.Our research not only identifies novel targets and pathways for the clinical diagnosis and treatment of TAO but also advances the innovation in traditional Chinese medicine through the elucidation of the SMYA/miR-548j-5p/IL-17A regulatory axis in the pathogenesis of TAO.展开更多
OBJECTIVE： To observe if integrated treatment is better than other therapies for lower-limb stage Ⅱ thromboangiitis obliterans （TAO）. METHODS： Ninety lower-limb stage Ⅱ or worse TAO patients were randomly divide...OBJECTIVE： To observe if integrated treatment is better than other therapies for lower-limb stage Ⅱ thromboangiitis obliterans （TAO）. METHODS： Ninety lower-limb stage Ⅱ or worse TAO patients were randomly divided into three groups： group A （30 cases） treated by intervention and oral administration of Chinese medicine; group B （30 cases） treated by intervention alone; and group C （30 cases） treated only with oral adminis- tration of Chinese medicine. Therapeutic effects were observed, including the cure rate; the recurrence rate after one month, three months, six months, nine months, and one year; the ankle brachial indexes; the incidence of complications; and the level of C-reactive protein and erythrocyte sedimentation rate.RESULTS： Group A had significantly better clinically curative effects, related indexes, and outcomes during the long-term follow-up survey, than that of groups B and C. CONCLUSION： Integrated treatment is more effective for treating lower-limb stage Ⅱ or worseTAO.展开更多
文摘Thromboangiitis Obliterans (TAO), a common peripheral vascular disease with a long illness course and grave sufferings, can cause acromelic gangrene, ulcer and even amputation at the late stage. We have for many years used TCM syndrome differentiation to diagnose and treat the disease with good therapeutic results. The treatment of 64 TAO cases from 2001 to 2002 is reported as follows.
文摘Objective:To study the correlation of peripheral blood nuclear factorκB (NF-κB) expression with cytokines and endothelial injury in patients with thromboangiitis obliterans (TAO).Methods:Patients who were diagnosed as lower limb thromboangiitis obliterans in Jining No. 1 People's Hospital between March 2014 and October 2017 were selected as the TAO group of the research, and healthy subjects who received physical examination in Jining No. 1 People's Hospital during the same period and had the general information matching that of TAO group were selected as the control group. The NF-κB expression intensity in peripheral blood as well as the contents of cytokines and endothelial injury indexes in serum was determined.Results: NF-κB expression intensity in peripheral blood of TAO group was significantly higher than that of control group;serum ICAM-1, VCAM-1, E-selectin, TGF-β1, IL-10, TXB2, vWF, D-D, HIF-1 and VEGF levels of TAO group were significantly higher than those of control group whereas 6-Keto-PGF1 level was significantly lower than that of control group, and serum ICAM-1, VCAM-1, E-selectin, TGF-β1, IL-10, TXB2, vWF, D-D, HIF-1 and VEGF levels of TAO group of patients with high NF-κB expression were significantly higher than those of patients with low NF-κB expression whereas 6-Keto-PGF1 level was significantly lower than that of patients with low NF-κB expression.Conclusion: The high expression of NF-κB in the peripheral blood of patients with TAO can promote the excessive secretion of inflammatory and immune cytokines and aggravate the endothelial cell injury.
文摘Thromboangiitis obliterans (TAO) is an unusual tobacco-associated vasculopathy that is a non- atherosclerotic inflammatory disorder of unkn- own etiology that affects small and medium- sized vessels of the extremities. The single guanosine nucleotide deletion/insertion polym- orphism (4G/5G) at -675 bp in promoter region of the PAI-1 gene is the major genetic determi- nant of PAI-1 expression. Plasma PAI-1 level is higher in people with the homozygous 4G genotype than in those with the 5G/5G genotype and renders higher transcription activity. The aim of this study was to determine the status and the role of PAI-1 gene 4G/5G promoter polymorphism in patients with Buerger's disease (Thromboangiitis obliterans—TAO). The current case-control study included 30 consecutive pat- ients with Buerger's disease (mean age 42.9 ± 14.3 years, 28 men and 2 women), and 30 healthy volunteers (mean age 40.9 ± 4.79 years, 27 men and 3 women) between January 2006 and September 2009. Patients and control cases were genotyped for the 4G/5G polymorphism using the multiplex PCR based stripassay reverse hybridisation technique. It was found that heterozygote PAI-1 gene polymorphisms (p < 0.05) was significantly more frequent in patients with TAO in the current results. There was a significant difference in genotype distribution between the two groups (P < 0.001). The 4G allele occurred more frequently in the patient group of heavy smokers (P = 0.05). The current study shows the higher prevalence of of 4G allele in TAO patients in Sivas population means gene may predispose to TAO.
基金supported by the Natural Sci-ence Foundation of China(No.82274575)Co-construction Project of State Administration of TCM(Nos.GZY-KJS-SD-2023-034,GZY-KJS-SD-2023-046)+4 种基金Major Basic Research Project of Natural Science Foundation of Shandong Province(No.ZR2023ZD56)the Joint Fund of Natural Science Foundation of Shandong(No.ZR2022LZY011)the Central Government Guides Local Science and Technology Development Fund Projects of Shandong Province(No.YDZX20203700001407)Taishan Scholars(No.Tsqn201812125)National Youth Qihuang Scholar Training Program,Shandong Province Traditional Chinese Medicine High Level Talent Cultivation Project and Key research and development project of Shandong Province(No.2020CXGC010505).
文摘Thromboangiitis obliterans(TAO)is a rare,chronic,progressive,and segmental inflammatory disease characterized by a high rate of amputation,significantly compromising the quality of life of patients.Si-Miao-Yong-An decoction(SMYA),a tradition-al prescription,exhibits anti-inflammatory,anti-thrombotic,and various other pharmacological properties.Clinically,it was fully proved to be effective for TAO therapy,but the specific therapeutic effect of SMYA on TAO has been unknown.Thus,deep unveiling the mechanism of SMYA in TAO for identifying clinical therapeutic targets is extremely important.In this study,we observed elev-ated levels of IL-17A in the peripheral blood mononuclear cells(PBMCs)of TAO patients,whereas the expression of miR-548j-5p was significantly decreased.A negative correlation between the levels of miR-548j-5p and IL-17A was also demonstrated.In vitro ex-periments showed that overexpression of miR-548j-5p led to a decrease in IL-17A levels,whereas downregulation of miR-548j-5p showed the opposite effect.Using a dual luciferase assay,we confirmed that miR-548j-5p directly targets IL-17A.Furthermore,serum containing SMYA effectively decreased IL-17A levels by increasing the expression of miR-548j-5p.More importantly,the results of in vivo tests indicated that SMYA mitigated the development of TAO by inhibiting IL-17A through the upregulation of miR-548j-5p in vascular tissues.In conclusion,SMYA significantly enhances the expression of miR-548j-5p,thereby reducing the levels of the target gene IL-17A and alleviating TAO.Our research not only identifies novel targets and pathways for the clinical diagnosis and treatment of TAO but also advances the innovation in traditional Chinese medicine through the elucidation of the SMYA/miR-548j-5p/IL-17A regulatory axis in the pathogenesis of TAO.
基金Supported by Gansu Province Science and Technology Plan Project,a Clinical Comparative Study of the Effect of Combined Interventional Approach and Traditional Chinese Medicine on Thromboangiitis Obliterans of Stage Ⅱ and above(No.12077TCYA018)
文摘OBJECTIVE： To observe if integrated treatment is better than other therapies for lower-limb stage Ⅱ thromboangiitis obliterans （TAO）. METHODS： Ninety lower-limb stage Ⅱ or worse TAO patients were randomly divided into three groups： group A （30 cases） treated by intervention and oral administration of Chinese medicine; group B （30 cases） treated by intervention alone; and group C （30 cases） treated only with oral adminis- tration of Chinese medicine. Therapeutic effects were observed, including the cure rate; the recurrence rate after one month, three months, six months, nine months, and one year; the ankle brachial indexes; the incidence of complications; and the level of C-reactive protein and erythrocyte sedimentation rate.RESULTS： Group A had significantly better clinically curative effects, related indexes, and outcomes during the long-term follow-up survey, than that of groups B and C. CONCLUSION： Integrated treatment is more effective for treating lower-limb stage Ⅱ or worseTAO.
